Seasonal variation of serum alpha- and beta-cryptoxanthin and 25-OH-vitamin D(3) in women with osteoporosis.
beta-Cryptoxanthin displays a unique anabolic effect on bone calcification. In women with osteoporosis, serum beta-cryptoxanthin and 25-OH-vitamin D(3) showed a weak but significant correlation and exhibited a complementary seasonal distribution. The potential role of beta-cryptoxanthin as a nutritional approach to improving bone health deserves further evaluation.


BACKGROUND
Dietary intake and serum levels of beta-cryptoxanthin have been inversely related to different bone and joint disorders and in vitro and animal studies have shown that beta-cryptoxanthin displays a unique anabolic effect on bone calcification. Due to the emerging role of beta-cryptoxanthin in bone biology, we aimed to assess the serum distribution and variability of beta-cryptoxanthin and their potential relation to 25-OH-vitamin D(3) in women with osteoporosis.


METHODS
Serum concentrations of alpha- and beta-cryptoxanthin and 25-OH- D(3) in women with osteoporosis (N = 644) were analyzed using a quality-controlled high-performance liquid chromatography (HPLC) method.


RESULTS
Overall, significant seasonal variations were found for the three analytes and inter-individual variation was also high (60-73%). beta-cryptoxanthin and 25-OH-vitamin D(3) exhibited a marked complementary seasonal distribution in serum, with vitamin D displaying the highest values in summer and beta-cryptoxanthin in winter.


CONCLUSIONS
Given the anabolic effect of beta-cryptoxanthin on bone calcification and its complementary seasonal distribution with respect to 25-OH-vitamin D(3), the potential role of beta-cryptoxanthin as a sustainable nutritional approach to improving bone health deserves to be further evaluated.
Granado-Lorencio
F
F
Servicio de Bioquímica Clínica, Hospital Universitario Puerta de Hierro, Unidad de Vitaminas, 28035, Madrid, Spain. fgranado.hpth@salud.madrid.org
Olmedilla-Alonso
B
B
Herrero-Barbudo
C
C
Blanco-Navarro
I
I
Pérez-Sacristán
B
B
D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000502:physiology; D001862:Bone Resorption / Q000628:therapy*; D002762:Cholecalciferol / Q000097:blood*; D065366:Cryptoxanthins; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood* / Q000517:prevention & control; D012621:Seasons; D014808:Vitamin D Deficiency / Q000097:blood* / Q000628:therapy; D024341:Xanthophylls / Q000097:blood*
D015415:Biomarkers; D065366:Cryptoxanthins; D024341:Xanthophylls; D002762:Cholecalciferol